Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, today announced its Scientific Advisory Board made up of Drs. Marc Abrams, David Bredt and James Treanor.
Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.
With an aim to make more precise genetic medicines, Switch Therapeutics emerged from stealth Tuesday with $52 million in venture funding. Switch is built on research into what it describes as “conditionally activated” small interfering RNA. The company claims it can design RNA molecules to be activated only in certain cells, potentially aiding their use in targeting central nervous system diseases.
Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells. CASi platform, based on technology developed at Caltech, Harvard and City of Hope, has broad therapeutic potential; initial efforts to focus on central nervous system…